Why Axsome Therapeutics Depression Study Is All Smiles

Health and Healthcare

Published: January 7, 2019 11:00 am

Last Updated: January 11, 2020 12:54 pm

Axsome Therapeutics Inc. (NASDAQ: AXSM) shares absolutely exploded on Monday after the company announced that its midstage trial in patients with major depressive disorder (MDD) met its primary endpoint.

Not only did the firm’s Phase 2 Ascend trial of AXS-05 in MDD meet the prespecified primary endpoint, but it also significantly improved symptoms of depression.

AXS-05 demonstrated a highly statistically significant reduction in the Montgomery-Åsberg Depression Rating Scale total score, averaged over the six-week treatment period, as compared to the antidepressant bupropion.

At week 6, 47% of patients who received AXS-05 achieved remission, compared with 16% of patients who received bupropion.

AXS-05 is also being evaluated in the Stride-1 Phase 3 trial in patients with treatment-resistant depression (TRD), defined as patients with MDD who have failed two or more antidepressant treatments. AXS-05 was granted Fast Track designation by the U.S. Food and Drug Administration (FDA) for the treatment of TRD. Considering the results of the Ascend trial, Axsome intends to meet with the FDA to define the potential regulatory path for the broader MDD population.

Professor Maurizio Fava, M.D., executive vice chair, Department of Psychiatry, Massachusetts General Hospital and associate dean for Clinical & Translational Research, Harvard Medical School, commented:

The clinically meaningful improvements in depressive symptoms seen with AXS-05 in this study were achieved versus an active comparator that is a well-established antidepressant, as early as only one week after initiation of treatment. Data show currently marketed antidepressants fail to provide adequate treatment response in about two thirds of treated patients. An estimated 16 million Americans suffer from major depressive disorder each year. As an oral NMDA receptor antagonist with multimodal activity, AXS-05 could provide a new approach to treating this potentially life-threatening condition.

Shares of Axsome were last seen up about 140% at $6.30, with a 52-week range of $1.94 to $7.24. The stock has a consensus analyst price target of $19.00.

24/7 Wall St.
Major Biopharma Catalysts Coming in the First Quarter of 2019

The Average American Has No Idea How Much Money You Can Make Today ^(Sponsor)

The last few years made people forget how much banks and CD’s can pay. Meanwhile, interest rates have spiked and many can afford to pay you much more, but most are keeping yields low and hoping you won’t notice.

But there is good news. To win qualified customers, some accounts are paying almost 10x the national average! That’s an incredible way to keep your money safe and earn more at the same time. Our top pick for high yield savings accounts includes other benefits as well. You can earn up to 3.80% with a Checking & Savings Account today Sign up and get up to $300 with direct deposit. No account fees. FDIC Insured.

Click here to see how much more you could be earning on your savings today. It takes just a few minutes to open an account to make your money work for you.

Our top pick for high yield savings accounts includes other benefits as well. You can earn up to 4.00% with a Checking & Savings Account from Sofi. Sign up and get up to $300 with direct deposit. No account fees. FDIC Insured.

¹https://www.fdic.gov/national-rates-and-rate-caps